Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Non-inferiority in the Intraocular Pressure Decrease of the Preservative-free Ophthalmic Solution PRO-122 Versus Concomitant Therapy in Subjects With Uncontrolled Primary Open-angle Glaucoma

Next Previous
Trial Profile

A Non-inferiority in the Intraocular Pressure Decrease of the Preservative-free Ophthalmic Solution PRO-122 Versus Concomitant Therapy in Subjects With Uncontrolled Primary Open-angle Glaucoma

Status: Discontinued
Phase of Trial: Phase III

Latest Information Update: 10 Mar 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Brimonidine/dorzolamide/timolol (Primary) ; Brimonidine; Dorzolamide; Timolol
  • Indications Open-angle glaucoma
  • Focus Registrational; Therapeutic Use
  • Acronyms PRO-122LATAM
  • Sponsors Laboratorios Sophia

Most Recent Events

  • 06 Mar 2025 Status changed from recruiting to discontinued.
  • 05 Dec 2023 Planned End Date changed from 30 Jun 2023 to 30 Jun 2024.
  • 05 Dec 2023 Planned primary completion date changed from 30 Jun 2023 to 30 Jun 2024.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top